Navigation Links
Clinical Study With Investigational Cream Aims To Help Women Who Experience Painful Sex

NEW YORK, Sept. 4, 2012 /PRNewswire/ -- NeoGyn Vulvar Soothing Cream is sponsoring a clinical study held in four medical centers throughout the United States to test the effectiveness of an investigational cream.

(Photo: )

The study is being conducted at The Centers for Vulvovaginal Disorders in Washington DC, Pelvic & Sexual Health Institute in Philadelphia, PA, San Diego Sexual Medicine in San Diego, CA and Arizona Vulva Clinic. Additional applicants are needed for each location to participate in the randomized, double- blind, placebo controlled Research Study to evaluate a vulvar soothing cream containing cutaneous lysate for vulvar use.

Provoked vestibulodynia is classified as spontaneous pain in the vulvar region. The condition is typically characterized by pain at the entry point into the vagina during tampon insertion or sexual intercourse. Causes of provoked vestibulodynia can vary, which contributes to making it difficult for doctors to diagnose and treat this condition.

Each three month study will be led by physicians specialized in the field of women's health and vulvar care including, Dr. Andrew Goldstein, MD, Dr. Kristene Whitmore, MD and Dr. Susan Kellogg PhD, Dr. Irwin Goldstein, MD, and Dr. Joseph Brooks, MD. After inclusion, participants will attend one follow-up clinic visit, two telephone interviews and complete several questionnaires over the course of the study. The study cream and other study related tests, procedures and visits will be provided at no cost to each selected participant.

Eligible applicants are women who live in close proximity to the study sites and are 20-55 years old. Participants cannot be pregnant or breast-feeding and should be in a heterosexual relationship where a reliable form of birth control is being used. Pain experienced with the use of tampons or from intercourse are the top pre-requisites along with no medical history of heart disease, HIV, hepatitis B or C, or being post- menopausal.

NeoGyn's sponsorship of this clinical trial demonstrates the company's commitment to search for solutions in helping women with vulvar pain. The company's mission is also to help educate women and physicians on this not uncommon condition. NeoGyn encourages women to remain persistent in their quest for an accurate diagnosis and solution for vulvodynia

For more information about this clinical study or to see if you qualify, visit For more information on vestibulodynia, visit,, or

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
(Date:12/1/2015)... 1, 2015  Eyeon Therapeutics has received a ... treatments based on a charged hydrophilic polymer developed ... The product has been shown to be safe ... Mark Mitchnick , MD, CEO states, "This ... additional polymers in conjunction with a therapeutic agent.  ...
(Date:12/1/2015)... 1, 2015  Athletic apparel company Tommie ... to pay $1.35 million to settle Federal Trade ... copper-infused compression clothing would relieve severe and chronic ... diseases. Tommie Copper,s proposed ... and its founder and chairman Thomas Kallish ...
(Date:12/1/2015)... diciembre de 2015  AccuTEC Blades, una ... precisión, develó hoy un nuevo logo corporativo ... El nuevo logo destaca la experiencia de ... de productos con cuchillas donde "el borde ... --> ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... The Multiple System Atrophy Coalition has announced the launch of its MSA Can’t ... today to coincide with Giving Tuesday 2015, a global day of fundraising. , ... be productive, to do simple daily activities like walking to the mailbox and eating ...
(Date:12/1/2015)... ... December 01, 2015 , ... Royal River Natural Foods — a locally-owned, ... post-menopausal women who took the nutritional supplement creatine, along with resistance training for a ... not take creatine. , The report is part of the December 2015 issue of ...
(Date:12/1/2015)... ... 2015 , ... Baptist Medical Center Jacksonville has implanted the ... hospital in the region providing what is known as the world’s smallest pacemaker. ... revealed recently at a medical conference and published in The New England Journal ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... to continue the expansion of the company’s growing product line of food safety ... (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of ... often catastrophic contributors to diseases of the diabetic foot. The American Board ...
Breaking Medicine News(10 mins):